Pyxis Oncology (PYXS) to Release Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $16.15 million during the quarter. On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS traded down $0.06 during trading on Tuesday, hitting $1.14. 29,660 shares of the stock were exchanged, compared to its average volume of 734,546. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.39. The company's fifty day simple moving average is $1.05 and its 200-day simple moving average is $1.78. The company has a market capitalization of $70.31 million, a price-to-earnings ratio of -1.10 and a beta of 1.15.

Hedge Funds Weigh In On Pyxis Oncology

A hedge fund recently raised its stake in Pyxis Oncology stock. Bank of America Corp DE increased its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 20.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,745 shares of the company's stock after acquiring an additional 9,062 shares during the period. Bank of America Corp DE owned about 0.09% of Pyxis Oncology worth $84,000 as of its most recent SEC filing. 39.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on PYXS shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Pyxis Oncology has an average rating of "Moderate Buy" and an average target price of $9.20.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.